Merozoite Surface Protein 1 of Plasmodium vivax Induces a Protective Response against Plasmodium cynomolgi Challenge in Rhesus Monkeys
- 1 September 2005
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 73 (9) , 5936-44
- https://doi.org/10.1128/iai.73.9.5936-5944.2005
Abstract
The 42-kDa fragment of the merozoite surface protein 1 (MSP-1 42 ) is a leading candidate for the development of a vaccine to control malaria. We previously reported a method for the production of Plasmodium vivax MSP-1 42 (PvMSP-1 42 ) as a soluble protein (S. Dutta, L. W. Ware, A. Barbosa, C. F. Ockenhouse, and D. E. Lanar, Infect. Immun. 69: 5464-5470, 2001). We report here a process to manufacture the same PvMSP-1 42 protein but as an insoluble inclusion body-derived protein which was then refolded in vitro. We compared the immunogenicity and protective efficacy of the soluble and refolded forms of PvMSP-1 42 protein by using a heterologous but closely related P. cynomolgi -rhesus monkey challenge model. As comparative controls we also expressed, purified, and immunized rhesus with the soluble and refolded forms of the P. cynomolgi MSP-1 42 (PcMSP-1 42 ) proteins. All proteins induced equally high-titer, cross-reacting antibodies. Upon challenge with P. cynomolgi , none of the MSP-1 42 -vaccinated groups demonstrated sterile protection or a delay in the prepatent period. However, following an initial rise in parasitemia, all MSP-1-vaccinated animals had significantly lower parasite burdens as indicated by lower cumulative parasitemia, lower peak parasitemia, lower secondary peak parasitemia, and lower average daily parasitemia compared to the adjuvant control group ( P < 0.05). Except the soluble PcMSP-1 42 group, monkeys in all other groups had fewer numbers of days with parasitemia of >10,000 parasites mm −3 . Interestingly, there was no significant difference in the level of partial protection observed in the homologous and heterologous groups in this challenge model. The soluble and refolded forms of PcMSP-1 42 and PvMSP-1 42 proteins also appeared to have a similar partially protective effect.Keywords
This publication has 42 references indexed in Scilit:
- Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720Vaccine, 2005
- The Clinical-Grade 42-Kilodalton Fragment of Merozoite Surface Protein 1 ofPlasmodium falciparumStrain FVO Expressed inEscherichia coliProtectsAotus nancymaiagainst Challenge with Homologous Erythrocytic-Stage ParasitesInfection and Immunity, 2005
- Comparison of Immunogenicities of RecombinantPlasmodium vivaxMerozoite Surface Protein 1 19- and 42-Kilodalton Fragments Expressed inEscherichia coliInfection and Immunity, 2004
- Nature and Specificity of the Required Protective Immune Response That Develops Postchallenge in Mice Vaccinated with the 19-Kilodalton Fragment ofPlasmodium yoeliiMerozoite Surface Protein 1Infection and Immunity, 2002
- Purification, Characterization, and Immunogenicity of the Refolded Ectodomain of the Plasmodium falciparum Apical Membrane Antigen 1 Expressed in Escherichia coliInfection and Immunity, 2002
- Protective Immune Responses to the 42-Kilodalton (kDa) Region ofPlasmodium yoeliiMerozoite Surface Protein 1 Are Induced by the C-Terminal 19-kDa Region but Not by the Adjacent 33-kDa RegionInfection and Immunity, 2002
- Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum11Edited by J. A. WellsJournal of Molecular Biology, 2001
- Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteersVaccine, 2000
- A reticulocyte-binding protein complex of plasmodium vivax merozoitesCell, 1992
- IMMUNE RESPONSE OF MAN TO INOCULATION WITH PLASMODIUM CYNOMOLGI AND CHALLENGE WITH P. VIVAXThe Lancet, 1966